

Medication Audit Criteria and Guidelines

Diphenhydramine (Benadryl®)

Hydroxyzine (Vistaril®, Atarax® [DSC])

PEFC Approved: July 2023

Indications

If a medication is prescribed for an off-label indication, documentation in the patient chart is recommended.

Label:

- Anxiety
- Insomnia (diphenhydramine)
- Parkinsonism and other EPS (diphenhydramine)

Off Label:

Insomnia (hydroxyzine)

Black Box Warning

None

Contraindications

- Anticholinergic intoxication
- Delirium
- Early pregnancy (hydroxyzine)
- Hypersensitivity to medication prescribed
- Prolonged QT interval (hydroxyzine, diphenhydramine) or risk factors for QT prolongation (hydroxyzine doses ≥100mg) such as concomitant QT prolonging medications, electrolyte imbalance, pre-existing heart disease, family history of congenital long QT syndrome

Warnings and Precautions

- Diagnosis of cardiovascular disease (hypertension, ischemic heart disease, etc.) (diphenhydramine)
- Disease states where increased anticholinergic activity may complicate disease course (narrow angle glaucoma, benign prostatic hypertrophy, etc.)

- Elderly, debilitated patients
- Hepatic impairment (hydroxyzine)
- Known hypersensitivity to cetirizine or levocetirizine (hydroxyzine)
- Patient with thyroid dysfunction (diphenhydramine)
- Pregnancy and nursing mothers
- Renal impairment (hydroxyzine)
- Respiratory impairment or diagnosis of respiratory disease (asthma, emphysema, chronic bronchitis)
- Risk factors for QT prolongation (hydroxyzine doses <100mg) such as concomitant QT prolonging medications, electrolyte imbalance, pre-existing heart disease, family history of congenital long QT syndrome
- Urinary retention
- Use with other anticholinergic medications
- Use with other CNS depressants or sedatives

Adverse Reactions

Side Effects Which Require Medical Attention

- Delirium
- Over-sedation, dizziness, or lightheadedness
- Pain with, or change in frequency of urination
- QT prolongation (hydroxyzine)
- Severe anticholinergic side effects (mydriasis, tachycardia, urinary retention, hypotension, constipation, arrhythmia, etc.)
- Worsening confusion or agitation

Drug Interactions of Major Significance

See: Contraindications

See: Indiana Univ Drug Interaction Table

See: Lexicomp, Micromedex for more information

Special Populations

- Pediatrics/Adolescents
 - ▶ See "Psychotropic Medication Utilization Parameters for Children and Youth in Texas Public Behavioral Health (6th Version)" for specific details.
- Geriatric
 - Included in Beers Criteria. Use caution or avoid use as potentially inappropriate in older adults.
 - ► Hydroxyzine dose cautiously by starting on the lower end of the dosing range
- Renal

- ▶ Diphenhydramine no specific labeling recommendations
- Hydroxyzine
 - ♦ CrCl ≥ 50 ml/min no adjustment recommended
 - ♦ CrCl 10 to < 50 ml/min 50% of normal dose
 - ♦ CrCl <10 ml/min 25% to 50% of normal dose
- Hepatic
 - ▶ Diphenhydramine no specific labeling recommendations
 - ► Hydroxyzine in adults with primary biliary cirrhosis, change dosing interval to every 24 hours
- Pregnancy and Breastfeeding
 - ► See Contraindications (hydroxyzine) and Warnings and Precautions (diphenhydramine, hydroxyzine).
 - ▶ Review product-specific labeling. Consider risks/benefits in reviewing medication-specific labeling.

Patient Monitoring Parameters

Baseline Tests:

Pregnancy test (females)

Ongoing Tests:

Pregnancy test (females) as clinically indicated

Dosing

- See HHSC Psychiatric Drug Formulary for dosage guidelines.
- If a medication is prescribed at dosages in excess of the Psychotropic Dosage Guidelines found in the HHS Psychiatric Drug Formulary, documentation in the patient chart is recommended.